JP2021061852A5 - - Google Patents

Download PDF

Info

Publication number
JP2021061852A5
JP2021061852A5 JP2021001276A JP2021001276A JP2021061852A5 JP 2021061852 A5 JP2021061852 A5 JP 2021061852A5 JP 2021001276 A JP2021001276 A JP 2021001276A JP 2021001276 A JP2021001276 A JP 2021001276A JP 2021061852 A5 JP2021061852 A5 JP 2021061852A5
Authority
JP
Japan
Prior art keywords
protein
library
candidate protein
binding site
candidate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021001276A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021061852A (ja
JP7109605B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2021061852A publication Critical patent/JP2021061852A/ja
Publication of JP2021061852A5 publication Critical patent/JP2021061852A5/ja
Application granted granted Critical
Publication of JP7109605B2 publication Critical patent/JP7109605B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021001276A 2015-05-21 2021-01-07 タンパク質の特徴を改善する方法 Active JP7109605B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562165173P 2015-05-21 2015-05-21
US62/165,173 2015-05-21

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017556995A Division JP6867302B2 (ja) 2015-05-21 2016-05-16 タンパク質の特徴を改善する方法

Publications (3)

Publication Number Publication Date
JP2021061852A JP2021061852A (ja) 2021-04-22
JP2021061852A5 true JP2021061852A5 (https=) 2021-07-29
JP7109605B2 JP7109605B2 (ja) 2022-07-29

Family

ID=57320465

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017556995A Active JP6867302B2 (ja) 2015-05-21 2016-05-16 タンパク質の特徴を改善する方法
JP2021001276A Active JP7109605B2 (ja) 2015-05-21 2021-01-07 タンパク質の特徴を改善する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017556995A Active JP6867302B2 (ja) 2015-05-21 2016-05-16 タンパク質の特徴を改善する方法

Country Status (5)

Country Link
US (2) US10526597B2 (https=)
EP (1) EP3297661B1 (https=)
JP (2) JP6867302B2 (https=)
ES (1) ES2881683T3 (https=)
WO (1) WO2016187101A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2881683T3 (es) 2015-05-21 2021-11-30 Full Spectrum Genetics Inc Procedimiento para mejorar las características de las proteínas
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
EP3493844A4 (en) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2018098356A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Psma targeting trispecific proteins and methods of use
AU2017363300A1 (en) 2016-11-23 2019-06-20 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
EP3621994A4 (en) 2017-05-12 2020-12-30 Harpoon Therapeutics, Inc. MESOTHELIN BINDING PROTEINS
WO2018209304A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
MX2020003915A (es) 2017-10-13 2020-10-08 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso.
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
BR112020023330A2 (pt) 2018-05-14 2021-04-20 Harpoon Therapeutics, Inc. porção de ligação para ativação condicional de moléculas de imunoglobulina
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
AU2020275002A1 (en) 2019-05-14 2021-12-23 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
CN115768463A (zh) 2020-02-21 2023-03-07 哈普恩治疗公司 Flt3结合蛋白及使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2079802C (en) 1990-04-05 2001-09-18 Roberto Crea Walk-through mutagenesis
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6117679A (en) * 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
AU1456101A (en) 1999-11-03 2001-05-14 Maxygen, Inc. Antibody diversity generation
ATE384129T1 (de) * 2001-11-22 2008-02-15 Univ Keio Künstliche antikörperbibliothek mit super- repertoire
EP2272566A3 (en) 2003-08-18 2013-01-02 MedImmune, LLC Humanisation of antibodies
US20060228350A1 (en) 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
US20060160178A1 (en) * 2003-11-17 2006-07-20 Jonathan Rothberg Methods of generating antibody diversity in vitro
CA2572917C (en) 2004-07-06 2012-04-03 Bioren Inc. Look-through mutagenesis for developing altered polypeptides with enhanced properties
US8633139B2 (en) 2007-12-21 2014-01-21 Abbvie Biotherapeutics Inc. Methods of screening complex protein libraries to identify altered properties
US20120077691A1 (en) 2010-09-24 2012-03-29 Full Spectrum Genetics, Inc. Method of analyzing binding interactions
JP5920835B2 (ja) * 2010-12-01 2016-05-18 田辺三菱製薬株式会社 無細胞翻訳系でFabを提示しうるポリヌクレオチド構築物ならびにそれを用いたFabの製造方法およびスクリーニング方法
US20120258866A1 (en) 2011-04-05 2012-10-11 Full Spectrum Genetics, Inc. Multi-dimensional selection of protein mutants using high throughput sequence analysis
US10947305B2 (en) 2015-03-20 2021-03-16 Full Spectrum Genetics, Inc. Anti-TNFα binding compounds and uses thereof
ES2881683T3 (es) 2015-05-21 2021-11-30 Full Spectrum Genetics Inc Procedimiento para mejorar las características de las proteínas

Similar Documents

Publication Publication Date Title
JP2021061852A5 (https=)
JP2025037968A (ja) 単一ドメイン抗体のバリアント核酸ライブラリー
KR20230016184A (ko) 코로나바이러스에 대한 변이체 핵산 라이브러리
KR20210144698A (ko) 항체 최적화를 위한 변이 핵산 라이브러리
US20130059741A1 (en) Binding assays for markers
Spiliotopoulos et al. Sensitive recovery of recombinant antibody clones after their in silico identification within NGS datasets
WO2023091614A2 (en) Dickkopf-1 variant antibodies and methods of use
CN102449476B (zh) 筛选抑制目标蛋白质-蛋白质相互作用的候选新药以开发一类药物的方法
EP1003853B1 (en) Methods for protein screening
Lind et al. Systematic analysis of phosphotyrosine antibodies recognizing single phosphorylated EPIYA-motifs in CagA of Western-type Helicobacter pylori strains
CN108149325A (zh) Dna编码动态分子库的合成与筛选方法
Nithun et al. Deciphering the role of the Ser‐phosphorylation pattern on the DNA‐binding activity of max transcription factor using chemical protein synthesis
Cheng et al. Characterization of moso bamboo (Phyllostachys edulis) Dof transcription factors in floral development and abiotic stress responses
Rohden et al. Through the looking glass: milestones on the road towards mirroring life
RU2014102617A (ru) Выявление аффинно-зрелых человеческих антител
KR101508219B1 (ko) 포도상구균의 테이코산에 대한 rna 앱타머
CN112941634B (zh) 通过dna编码化合物库筛选同时结合多个生物靶标的化合物的方法
Shahsavarian et al. Exploitation of rolling circle amplification for the construction of large phage-display antibody libraries
WO2024112948A1 (en) Chromatin profiling compositions and methods
CN102719443A (zh) 一种羧基末端特异的抗人淀粉样蛋白单克隆抗体基因和其编码多肽及应用
Kalichuk et al. Affitins: ribosome display for selection of Aho7c-based affinity proteins
Kitamura et al. Development of systemic in vitro evolution and its application to generation of peptide-aptamer-based inhibitors of cathepsin E
McCarthy et al. Altering the fine specificity of an anti-Legionella single chain antibody by a single amino acid insertion
JP2020534796A (ja) エピトープ翻訳後修飾状態に特異的な抗体の開発方法及び開発のための組成物
He et al. Production of protein arrays by cell-free systems